Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Debate

Set Alert for Pricing Debate

Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.

Market Access Pricing Strategies Pricing Debate

Latest From Pricing Debate

Brazil Makes Drug Prices Transparent To Strengthen Hand In Pricing Talks

Brazil wants to drive competition and lower drug prices by obliging health authorities to publish the prices paid for all drugs bought by the national health system. A voluntary system has already helped save $1bn and cut the price of Gilead’s Sovaldi by around 30%.

BioPharmaceutical Market Access

FDA and Drug Pricing: Lowering The Cost of Capital – Not The Cost Of Drugs

FDA regulatory reforms have been framed as part of the drug pricing debate. Commissioner Gottlieb has reframed the goal as lowering the cost of capital by increasing predictability. That probably won’t lower drug prices – but it might lower the cost of future acquisitions for drug companies.

FDA Pricing Debate

Brand 'Evergreening' Piques FDA Interest, But Solutions Remain Elusive

Agency eager to hear suggestions on the subject, also known as product hopping, but even reform advocates were cautious of stifling meaningful reformulations of products.

Generic Drugs Life Cycle Management

Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?

Payer groups suggest during FDA's Hatch-Waxman meeting that agency prioritize NDAs moving into the same class to push prices lower.

Pricing Debate Generic Drugs

The Value Lab: Moving Value-Based Health Care From Theory To Practice

Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.

BioPharmaceutical Reimbursement

340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach

There appears to be bipartisan interest in beefing up HRSA’s ability to oversee the 340B program – but the next step is likely to be more hearings and fact-finding, not immediate legislative changes.

Pricing Debate Legislation

340B Squeeze Begins: New HRSA Head Doesn’t Tip His Hand

HRSA Administrator George Sigounas made his public debut during the annual 340B coalition summer conference in Washington, DC. The setting was significant giving the prominence of the drug discount program on the Trump Administration agenda, but Sigounas didn’t offer much insight into the potential changes to come.

Healthcare Systems Reimbursement

Closing The Spread: 340B Providers Face Sharp Cuts Under Medicare Proposal

Medicare payments to hospitals for drugs provided under the 340B program would be reduced to average sales price (ASP) minus 22.5%, which CMS believes is more closely aligned with the discounted price obtained by the providers.

Medicare Pricing Debate

Medicare Spending Growth Won't Trigger IPAB Cost Reduction Plan

Threat of Independent Payment Advisory Board action to lower drug spending in Medicare alleviated for another year. Estimated spending growth in the program does not reach targets that would prompt cuts.

Medicare Pricing Debate
See All